HAV Vaccines

FDA License Received To Market Vaqta Vaccine

Published in Blood Weekly, April 22nd, 1996

Hepatitis A Vaccine, Inactivated (Vaqta), a vaccine developed by Merck & Co., Inc., West Point, Pennsylvania, for the prevention of hepatitis A, has been licensed by the U.S. Food and Drug Administration (FDA).

The product is scheduled to be available in May 1996. Vaqta is indicated for active immunization against disease caused by hepatitis A virus (HAV) in persons two years of age and older. Hepatitis A is a highly contagious virus that attacks the liver.

Approximately 27,000 cases of the disease were reported to the U.S. Centers for Disease Control and Prevention (CDC) in 1994. However, the CDC estimates there are approximately 143,000...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1996-04-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry